VERBIO Vereinigte BioEnergie AG (VBK)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 28.48 |
|---|---|
| 52-week range | 14.70 – 47.26 |
| Return, 1 month / 3 months | −10.4% / −15.8% |
| Return, 1 year / 3 years | +88.9% / −18.3% |
| Trend | Below its 200-day average |
| RSI (14) | 51 |
| Volatility (1 year) | 67.0% |
| Worst drawdown (1 year) | -45.9% |
| Average daily value traded | 2.77M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
VERBIO Vereinigte BioEnergie AG produces biofuels from agricultural raw materials. The company makes biodiesel and bioethanol, and it also produces biomethane for use as a fuel. Its customers are fuel distributors, oil companies and other users of transport fuels, mainly in Germany and elsewhere in Europe. VERBIO is based in Leipzig, Germany, and runs production plants that turn crops such as rapeseed and grain into renewable fuels and related by-products.
VERBIO Vereinigte BioEnergie AG trades under the code VBK on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
VERBIO Vereinigte BioEnergie AG (VBK) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 28.48 on 23 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 497 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 88.9% and over the last three months it fell 15.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 30 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.1% | ||
| From 52-week high | -37.8% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -15.8% | ||
| 6-month return | -30.9% | ||
| 12-month return, skipping the last month | 110.9% | ||
| Stability (higher is calmer) | 17 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 67.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.9% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 2.77M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.6% |
|---|---|
| 1 month | −10.4% |
| 3 months | −15.8% |
| 6 months | −30.9% |
| 1 year | +88.9% |
| 3 years | −18.3% |
| 5 years | −54.3% |
Signals
| 50-day / 200-day average | 29.61 / 31.69 |
|---|---|
| Golden / death cross (60 days) | Death, 21 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Dec 2024 | EUR 0.2000 |
| 5 Feb 2024 | EUR 0.2000 |
| 6 Feb 2023 | EUR 0.2000 |
| 7 Feb 2022 | EUR 0.2000 |
| 1 Feb 2021 | EUR 0.2000 |
| 3 Feb 2020 | EUR 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.